Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
4.200
-0.030 (-0.71%)
May 13, 2025, 4:00 PM - Market closed
Company Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States.
The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus.
It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.
Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Kezar Life Sciences, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Christopher Kirk |
Contact Details
Address: 4000 Shoreline Court, Suite 300 South San Francisco, California 94080 United States | |
| Phone | 650 822 5600 |
| Website | kezarlifesciences.com |
Stock Details
| Ticker Symbol | KZR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645666 |
| CUSIP Number | 49372L100 |
| ISIN Number | US49372L1008 |
| Employer ID | 47-3366145 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher J. Kirk Ph.D. | Co-Founder, Chief Executive Officer and Director |
| John Franklin Fowler | Co-Founder and Director |
| Mark Schiller | Chief Legal Officer |
| Dr. Jack Taunton Ph.D. | Co-Founder |
| Pattie Chiang | Principal Accounting Officer, Senior Vice President and Corporate Controller |
| Gitanjali Jain | Senior Vice President of Investor Relations and External Affairs |
| Joe Tedrick | Vice President of Human Resources |
| Dr. Neel K. Anand Ph.D. | Senior Vice President of Research and Drug Discovery |
| Zung To | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 25, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 21, 2025 | SCHEDULE 13G/A | Filing |